GL
GSK plc
GLAXF · OTC
$23.51 -6.72% (-$1.70)
1M -6.67%
Market Cap £72.5B
P/E Ratio 16.70x
Div. Yield 3.66%
ROE 25.57%
Bulios Fair Price
$30.73
30.7% upside
Current Price
$23.51
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GLAXF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
82 /100
Cheap P/E 16.70x
EV/EBITDA 8.86x
P/S 2.33x
Growth
35 /100
Stable EPS growth 27.58%
Rev. growth 3.66%
FCF growth 4.99%
Profitability
89 /100
Strong Gross margin 73.35%
Net margin 13.93%
Op. margin 18.33%
Quality
72 /100
Excellent ROIC 11.55%
ROE 25.57%
ROA 7.08%
Debt
64 /100
Moderate Debt/Equity 1.03x
Current ratio 0.82x
Int. coverage 11.82x
Stability
51 /100
Moderate Beta 0.30x
Rev. volatility 0.38%
EPS volatility 105.48%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GLAXF
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Luke Victor Miels
Employees
66,841
Headquarters
London
Upcoming events
28 OCT
Earnings
Upcoming earnings report